(Reuters) – Spectrum Prescription drugs stated on Monday the U.S. Meals and Drug Administration has deferred approval of its experimental drug for treating chemotherapy induced lack of white blood cells in most cancers sufferers, on account of COVID-19 associated journey restrictions.

The choice was taken because the U.S. well being company was unable to conduct an inspection of firm’s South Korea-based manufacturing plant, required earlier than drug approval, on account of restrictions on journey associated to the COVID-19 pandemic.

(Reporting By Mrinalika Roy in Bengaluru; Modifying by Shailesh Kuber)